All News

The Food and Drug Administration approved Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received two or more lines of therapy.

The Food and Drug Administration granted a Breakthrough Therapy Designation to Epkinly to treat patients with relapsed or refractory follicular lymphoma.

The Truqap-Faslodex treatment combination offers “more options” for some patients with HR-positive, HER2-negative breast cancer, an expert told CURE®.

If you have scanxiety, you aren't alone.

As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.

Treatment with Imfinzi for patients with advanced or metastatic NSCLC and limited physical performance status offered beneficial overall survival and maintained quality of life.

Analysis of molecular subtypes of muscle-invasive bladder cancer can predict if a tumor is likely to respond to chemotherapy before surgery but is not associated with differences in survival.

Although patient-facing AI could be more convenient in some settings, researchers delved into the ethical challenges and threats to patient dignity.

An expert discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.

Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’

A recent study revealed that patients with recurrent or metastatic non-small cell lung cancer tended to have better overall survival compared with those diagnosed with stage 4 disease.

Looking back, here’s what I would tell myself shortly after being diagnosed with cancer.

Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).

The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.

I have cancer and don't believe in god, can I still be spiritual?

Patients and their families facing financial burdens "don't have to try to carry the load all alone," as one ACCC Guidelines Task Force member tells CURE®.

A recent phase 2 trial revealed that the combination of Tafinlar and Mekinist benefitted children with BRAF-mutated low-grade gliomas.

A recent study found that healthy tissue near the sites of lung tumors may contain genetic information that could serve as a predictor of possible cancer recurrence.

In honor of National Family Caregiver’s Month, CURE® highlights some of the most important news in 2023.

Peer- and self-evaluated techniques are being incorporated to improve the sexual health of women with breast cancer.

Here's what I was asked during an AML patient workshop...

Immune checkpoint inhibitors can benefit patients in many ways, but especially with quality of life as the drugs are “very well-tolerated,” an expert said.

After being diagnosed with cancer, I decided to turn my “whys” and “what ifs” into education and advocacy work.

Dr. Nabil Rizk, chief of thoracic surgery at Hackensack University Medical Center, explains that segmentectomy is “just a little bit more of a refined way of treating cancers.”

The first patient has received TLX591, an antibody-based treatment for PSMA-positive metastatic castrate-resistant prostate cancer.

If metastatic breast cancer no longer responds to a given therapy, finding out what targetable mutations a patient has may guide the next steps for treatment, an expert said.

I see a psychologist who is helping me to understand my feelings and to learn mindfulness meditation techniques.

Maintenance treatment with Nexavar improved survival in patients with FLT3-ITD acute myeloid leukemia, research showed.